Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
BRD2 bromodomain (1-455 aa) (His-Tag), human recombinant protein
RING3, RNF3, Bromodomain containing 4, D6S113E, FSH, FSRG1, NAT, RING3, RNF3
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P25440 |
|---|---|
| Concentration | 1 |
| Calculated MW | 52.8 kDa (478 aa, 1-455 aa + His Tag), confirmed by MALDI-TOF. |
| Gene ID | 6046 |
|---|---|
| Gene Symbol | BRD2 |
| Other Names | RING3, RNF3, Bromodomain containing 4, D6S113E, FSH, FSRG1, NAT, RING3, RNF3 |
| Gene Source | Human |
| Source | E. coli |
| Assay&Purity | SDS-PAGE; ≥90% |
| Assay2&Purity2 | N/A; |
| Recombinant | Yes |
| Sequence | MGSSHHHHHH SSGLVPRGSH MGSMLQNVTP HNKLPGEGNA GLLGLGPEAA APGKRIRKPS LLYEGFESPT MASVPALQLT PANPPPPEVS NPKKPGRVTN QLQYLHKVVM KALWKHQFAW PFRQPVDAVK LGLPDYHKII KQPMDMGTIK RRLENNYYWA ASECMQDFNT MFTNCYIYNK PTDDIVLMAQ TLEKIFLQKV ASMPQEEQEL VVTIPKNSHK KGAKLAALQG SVTSAHQVPA VSSVSHTALY TPPPEIPTTV LNIPHPSVIS SPLLKSLHSA GPPLLAVTAA PPAQPLAKKK GVKRKADTTT PTPTAILAPG SPASPPGSLE PKAARLPPMR RESGRPIKPP RKDLPDSQQQ HQSSKKGKLS EQLKHCNGIL KELLSKKHAA YAWPFYKPVD ASALGLHDYH DIIKHPMDLS TVKRKMENRD YRDAQEFAAD VRLMFSNCYK YNPPDHDVVA MARKLQDVFE FRYAKMPD |
| Target/Specificity | BRD2 |
| Format | Liquid |
| Storage | -80°C; 1 mg/ml in Phosphate buffer saline (pH 7.4) containing 10% glycerol and 1 mM DTT. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The acetylation of histone lysine residues plays a crucial role in the epigenetic regulation of gene transcription. A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histones. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. These domains function in the linking of protein complexes to acetylated nucleosomes, thereby controlling chromatin structure and gene expression. Thus, bromodomains serve as “readers” of histone acetylation marks regulating the transcription of target promoters. The BET family of proteins, defined by tandem Bromodomains and an Extra Terminal domain, include BRD2, BRD3, BRD4, and BRDT. The BET proteins play a key role in many cellular processes, including inflammatory gene expression, mitosis, and viral/host interactions. The isolated individual or tandem bromodomains of BRD2 and BRD4 have been shown to bind acetylated histone tails, serving to couple histone acetylation marks to the transcriptional regulation of target promoters. Small molecule inhibitors of these interactions hold promise as useful therapeutics for human disease. This protein can be used for the study of bromodomain binding assays, screening inhibitors, and selectivity profiling.
References
Beck S.,et al.DNA Seq. 2:203-210(1992).
Thorpe K.L.,et al.Immunogenetics 44:391-396(1996).
Nomura N.,et al.Submitted (JUL-1997) to the EMBL/GenBank/DDBJ databases.
Bechtel S.,et al.BMC Genomics 8:399-399(2007).
Mungall A.J.,et al.Nature 425:805-811(2003).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
